Navigation Links
Sexual health of men with chronic heart failure significantly improves with CRT
Date:6/1/2011

A new study published in the journal Clinical Cardiology reveals that in men with chronic heart failure, cardiac resynchronization therapy (CRT) improves patients' libido, erectile dysfunction, and sexual performance.

Chronic heart failure (HF) is a common, complex clinical syndrome characterized by fatigue and exercise intolerance. HF patients experience decreased libido and erectile dysfunction (ED). CRT, which is a type of pacemaker that paces the right and left ventricle, is used to treat patients with HF.

Led by Ahmet Vural of Kocaeli University, researchers investigated the effects of CRT on libido and ED. 31 male patients with advanced HF, scheduled for implantation of a CRT device, were included in the study. They were assessed before and six months after CRT.

At the six-month follow-up after CRT, 23 patients reported no ED, and only two patients had moderate ED. Severe ED was not found in any patient. A significant increase in patients with normal libido was found, with 25 men reporting improvement compared to only three reporting normal libido prior to CRT.

The findings show that CRT results in significant improvement in libido, ED, and sexual performance as a consequence of the improvement in functional capacity and ejection fraction.

"Not only does CRT decrease mortality in heart failure patients, it also brings improvement in sexual health to the patient's life," Vural concludes.


'/>"/>

Contact: Amy Molnar
amolnar@wiley.com
Wiley-Blackwell
Source:Eurekalert

Page: 1

Related medicine news :

1. Controlling partners suffer more conflict with sexual desire
2. Viewers look to TV characters to advise how to talk about sexual health
3. Sexual orientation affects cancer survivorship
4. EDs should be aware of sexually transmitted infection risk in patients
5. Race a factor in whether young women are tested for sexually transmitted infections
6. Researchers need to engage lesbian, gay, bisexual, and transginder populations in health studies
7. Study finds surprising gender differences related to sexual harassment
8. Researchers: Sexually active teens need confidential health care
9. Tufts paper assesses effect of episodic sexual/physical activity on cardiac events
10. Sexual Side Effects From Propecia, Avodart May Be Irreversible
11. Brain cell regrowth linked to benefits of exercise, sexual behaviors and reproductive issues
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2016)... ... December 03, 2016 , ... The Lymphoma Research Foundation ... research and serving the lymphoma community through a comprehensive series of education programs, ... Event in New York City, with long-time partners The Paul Foundation, on November ...
(Date:12/4/2016)... Aliso Viejo, California (PRWEB) , ... December 04, ... ... self-animating lower third presets that have new attractive animation styles with unique displacement ... Pro3rd Displace features 30 pre-animated lower third designs. Choose from a variety of ...
(Date:12/2/2016)... , ... December 02, 2016 , ... Lori G. ... Traurig, LLP’s Atlanta office, will speak at the American Conference Institute’s 21st Drug ... Traurig is also a Lead Sponsor of the conference. , Cohen, who chairs the ...
(Date:12/2/2016)... ... December 02, 2016 , ... Advanced Inc., a leading provider of ... Bice, CPA, MBA to serve as Advanced Inc.’s Chief Financial Officer, effective December 1, ... Jason brings extensive financial and operational leadership experience to Advanced Inc. He began his ...
(Date:12/2/2016)... PA (PRWEB) , ... December 02, 2016 , ... With ... struggling through rehabilitation of an injury, patients must find the one that works for ... his pain, he created a machine that worked and decided to share it with ...
Breaking Medicine News(10 mins):
(Date:12/4/2016)...   Pairnomix, LLC, a genetic research company and ... the White House, today announced that findings from its first ... candidate therapies for a patient with epileptic encephalopathy caused by ... at the 70 th Annual Meeting of the ... , December 2-6, 2016.  Pairnomix, unique process involves ...
(Date:12/4/2016)... EAST HANOVER, N.J. , Dec. 3, 2016 /PRNewswire/ ... SEG101 (crizanlizumab, formerly SelG1), an anti-P-selectin antibody, reduced the ... by 45.3% compared to placebo (1.63 vs 2.98, p=0.010) ... Novartis today announced that the data are being featured ... American Society of Hematology (ASH) Annual Meeting and ...
(Date:12/4/2016)... Dec. 3, 2016  Findings from a Novartis ... CTL019, an investigational chimeric antigen receptor T cell ... young adult patients with B-cell acute lymphoblastic leukemia ... session at the 58th American Society of Hematology ... p.m.). The global Phase II study found that ...
Breaking Medicine Technology: